Shares of 10x Genomics rose significantly on Thursday, driven by investor enthusiasm over recent strategic developments. The company reported a new research collaboration with Cleveland Clinic and confirmed the closing of its acquisition of Proteintech Genomics. These moves are viewed by the market as expanding the firm's scientific capabilities and product pipeline.
The stock price increase coincided with analyst adjustments. While several analysts maintained neutral or equal-weight ratings on the stock, they raised their price targets to reflect the strengthened platform. The company’s year-to-date price performance has reached 129.74 percent, with an average trading volume of approximately 3.07 million shares. The current market capitalization stands at $4.76 billion.
Investors are also looking at the long-term revenue structure. A growing base of consumable products that require regular reordering is expected to help stabilize income. This recurring revenue model aims to smooth out the fluctuations associated with one-time instrument sales. However, analysts note that recent revenue declines and softer demand for new instruments could slow the expansion of the installed base. This may delay the point at which recurring consumable sales fully offset past weakness.
The article also covered Applied Materials, a U.S. chipmaking equipment supplier. Its shares jumped about 8 percent on Thursday. This movement followed bullish commentary from Chief Executive Gary Dickerson regarding demand visibility for the next two years. Dickerson stated that chipmakers are providing equipment demand forecasts extending through 2030 to keep capacity builds on track.
TD Cowen analyst Krish Sankar reaffirmed a Buy rating on Applied Materials and raised the price target by 33 percent, from $525 to $700. The company reported record second-quarter sales of $7.91 billion, a 20 percent increase from the previous year. Applied Materials has also doubled its advanced cleanroom capacity in Singapore to meet higher demand from chipmakers.
